Diffusion-Weighted Imaging of Acute Excitotoxic Brain Injury

References

1. ↵
   Hassel B, Boudingh KA, Narvesen C, et al. Glutamate transport, glutamine synthase and phosphate-activated glutamimnase in rat CNS white matter. A quantitative study. J Neurochem 2003;87:230–237

   CrossRefPubMed
2. ↵
   Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613–622

   CrossRefPubMedWeb of Science
3. ↵
   Sharp FR, Swanson RA, Honkaniemi J, et al. Neurochemistry and molecular biology. In: Barnett HJM, Mohr JP, Stein BM, et al. Stroke Pathophysiology, Diagnosis, and Management. 1998;54–56
4. ↵
   Buchan AM, Slivka A, Xue D. The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res 1992;574:171–177

   CrossRefPubMedWeb of Science
5. ↵
   Ogawa T, Okudera T, Inugami A, et al. Degeneration of the ipsilateral substantia nigra after striatal infarction: evaluation with MR imaging. Radiology 1997;204:847–851

   PubMed
6. ↵
   Battaglia G, Busceti CL, Pontarelli F, et al. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 2003;45:155–166

   CrossRefPubMedWeb of Science
7. ↵
   Nakase M, Tamura A, Miyasaka N, et al. Astrocytic swelling in the ipsilateral substantia nigra after occlusion of the middle cerebral artery in rats. AJNR Am J Neuroradiol 2001;22:660–663

   Abstract/FREE Full Text
8. Castillo M, Mukheriji SK. Early abnormalities related to postinfarction wallerian degeneration: evaluation with MR diffusion-weighted imaging. J Comput Assist Tomogr 1999;23:1004–1007

   CrossRefPubMedWeb of Science
9. Kang DW, Chu K, Yoon BW, Song IC, Chang KH, Roh JK. Diffusion-weighted imaging in wallerian degeneration. J Neurol Sci 2000;178:167–169

   CrossRefPubMedWeb of Science
10. ↵
    Kinoshita T, Moritani T, Shrier D, et al. Secondary degeneration of the substantia nigra and corticospinal tract after hemorrhagic middle cerebral artery infarction: Diffusion-weighted MR findings. Magn Reson Med Sci 2002;3:175–178
11. ↵
    Johnston MV. Neonatal hypoxic-ischemic brain insults and their mechanisms. In: New Concepts in Cerebral Ischemia. New York: CRC,2002;33–51
12. ↵
    Wolf RL, Zimmerman RA, Clancy R, et al. Quantitative apparent diffusion coefficient measurements in term neonates for early detection of hypoxic-ischemic brain injury: Initial experience. Radiology 2001;218:825–833

    PubMedWeb of Science
13. ↵
    Pu Y, Li QF, Zeng CM, et al. Increased detectability of alpha brain glutamate/glutamine in neonatal hypoxic-ischemic encephalopathy. AJNR Am J Neuroradiol 2000;21:203–212

    Abstract/FREE Full Text
14. ↵
    Ruppel RA, Kobanek PM, Adelson PD, et al. Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: The role of child abuse. J Pediatr 2001;138:18–25

    CrossRefPubMedWeb of Science
15. ↵
    Bullock R, Butcher SP, Chen MH, et al. Correlation of the extracellular glutamate concentration with extent of blood flow reduction after subdural hematoma in the rat. J Neurosurg 1991;74:794–802

    PubMedWeb of Science
16. Geddes JF, Hackshaw AK, Vowles GH, et al. Neuropathology of inflicted head injury in children. Patterns of brain damage. Brain 2001;124:1290–1298

    Abstract/FREE Full Text
17. ↵
    Suh DY, Davis PC, Hopkins KL, et al. Nonaccidental pediatric head injury: diffusion-weighted imaging findings. Neurosurgery 2001;49:309–320

    CrossRefPubMedWeb of Science
18. ↵
    Duhaime AC, Gennarelli LM, Boardman C. Neuroprotection by dextromethorphan in acute experimental subdural hematoma in the rat. J Neurotrauma 1996;13:79–84

    PubMed
19. Ikonomidou C, Qin Y, Labruyere J, Kirby C, et al. Prevention of trauma-induced neurodegeneration in infant rat brain. Pediatr Res 1996;39:1020–1027

    PubMedWeb of Science
20. ↵
    Smith SL, Hall ED. Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. J Neurotrauma 1998;15:707–719

    CrossRefPubMedWeb of Science
21. ↵
    Faden AI, Demediuk P, Panter SS, et al. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798–800

    Abstract/FREE Full Text
22. ↵
    Gennarelli TA. Mechanisms of brain injury [Suppl]. J Emerg Med 1993;11:5–11
23. ↵
    Liu AY, Maldjian JA, Bagley LJ, Sinson GP, et al. Traumatic brain injury: diffusion-weighted MR imaging findings. AJNR Am J Neuroradiol 1999;20:1636–1641

    Abstract/FREE Full Text
24. ↵
    Launes J, Siren J, Viinikka L, et al. Does glutamate mediate brain damage in acute encephalitis? Neuroreport 1998;9:577–581

    PubMedWeb of Science
25. ↵
    Fountain NB. Status epilepticus: risk factors and complications. Epilepsia 2000;41:S23–53
26. ↵
    Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. AJNR Am J Neuroradiol 2001;22:1813–1824

    FREE Full Text
27. ↵
    Chan S, Chin SS, Kartha K, et al. Reversible signal abnormalities in the hippocampus and neocortex after prolonged seizures. AJNR Am J Neuroradiol 1996;17:1725–1731

    Abstract
28. ↵
    Kim JA, Chung JI, Yoon PH, et al. Transient signal changes in patients with generalized tonic-clonic seizure or status epilepticus: periictal diffusion-weighted imaging. AJNR Am J Neuroradiol 2001;22:1149–1160

    Abstract/FREE Full Text
29. ↵
    Cohen-Gadol AA, Britton JW, Jack CR Jr, Friedman JA, Marsh WR. Transient postictal magnetic resonance imaging abnormality of the corpus callosum in a patient with epilepsy: case report and review of the literature. J Neurosurg 2002;97:714–717

    PubMedWeb of Science
30. ↵
    Kim SS, Chang KH, Kim ST, et al. Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol 1999;20:125–129

    Abstract/FREE Full Text
31. ↵
    Polster T, Hoppe M, Ebner A. Transient lesion in the splenium of the corpus callosum: three further cases in epileptic patients and a pathophysiological hypothesis. J Neurol Neurosurg Psychiatry 2001;70:459–463

    Abstract/FREE Full Text
32. ↵
    Domercq M, Matute C. Expression of glutamate transporters in the adult bovine corpus callosum. Brain Res Mol Brain Res 1999;67:296–302

    PubMed
33. ↵
    Maeda M, Shiroyama T, Tsukahara H, et al. Transient splenial lesion of the corpus callosum associated with antiepileptic drugs: evaluation by diffusion-weighted MR imaging. Eur Radiol 2003;13:1902–1906

    CrossRefPubMedWeb of Science
34. ↵
    Lien YH. Role of organic osmolytes in myelinolysis. A topographic study in rats after rapid correction of hyponatremia. J Clin Invest 1995;95:1579–1586
35. ↵
    Lexa FJ. Drug-induced disorders of the central nervous system. Semin Roentgenol 1995;30:7–17

    PubMed
36. ↵
    Weller M, Marini AM, Finiels-Marlier F. MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Eur J Pharmacol 1993;248:303–312

    PubMed
37. ↵
    Glushakov AV, Dennis DM, Sumners C. L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses. J Neurosci Res 2003;72:116–124

    CrossRefPubMedWeb of Science
38. ↵
    Huttenlocher PR. The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr 2000;159:S102–S106
39. ↵
    Pearsen KD, Gean-Marton AD, Levy HL, Davis KR. Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology 1990;177:437–440

    PubMedWeb of Science
40. ↵
    Phillips MD, McGraw P, Lowe MJ, Mathews VP, Hainline BE. Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria. AJNR Am J Neuroradiol 2001;22:1583–1586

    Abstract/FREE Full Text
41. ↵
    Kolker S, Mayatepek E, Hoffmann GF. White matter disease in cerebral organic acid disorders: clinical implications and suggested pathomechanisms. Neuropediatrics 2002;33:225–231

    CrossRefPubMed
42. ↵
    Antunez E, Estruch R, Cardenal C, Nicolas JM, Fernandez-Sola J, Urbano-Marquez A. Usefulness of CT and MR imaging in the diagnosis of acute Wernicke’s encephalopathy. AJR Am J Roentgenol 1998;171:1131–1137

    PubMedWeb of Science
43. ↵
    Chu K, Kang DW, Kim HJ, Lee YS, Park SH. Diffusion-weighted imaging abnormalities in wernicke encephalopathy: reversible cytotoxic edema? Arch Neurol 2002;59:123–127

    CrossRefPubMedWeb of Science
44. ↵
    Oka M, Terae S, Kobayashi R, et al. Diffusion-weighted MR findings in a reversible case of acute Wernicke encephalopathy. Acta Neurol Scand 2001;104:178–181

    CrossRefPubMed
45. ↵
    Doherty MJ, Watson NF, Uchino K, Hallam DK, Cramer SC. Diffusion abnormalities in patients with Wernicke encephalopathy. Neurology 200226;58:655–657
46. ↵
    Rugilo CA, Roca MC, Zurru MC, Gatto EM. Diffusion abnormalities and Wernicke encephalopathy. Neurology 200325;60:727–728
47. ↵
    Matute C, Alberdi E, Domercq M, et al. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001;24:224–230

    CrossRefPubMedWeb of Science
48. ↵
    Stover JF, Pleines UE, Morganti-Kossman MC, et al. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997;27:1038–1043

    CrossRefPubMedWeb of Science
49. ↵
    Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169–180

    CrossRefPubMedWeb of Science
50. ↵
    Ferrer I, Puig B. GluR2/3, NMDAepsilon1 and GABAA receptors in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 2003;106:311–318

    CrossRefPubMed
51. ↵
    Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412–1418

    CrossRefPubMedWeb of Science
52. ↵
    Molloy S, O’Laoide R, Brett F, Farrell M. The “Pulvinar” sign in variant Creutzfeldt-Jakob disease. AJR Am J Roentgenol 2000;175:555–556

    PubMed
53. ↵
    Haik S, Brandel JP, Oppenheim C, et al. Sporadic CJD clinically mimicking variant CJD with bilateral increased signal in the pulvinar. Neurology 2002;58:148–149

    FREE Full Text
54. ↵
    Demaerel P, Baert AL, Vanopdenbosch, et al. Diffusion-weighted magnetic resonance imaging in Creutzfeldt-Jakob disease. Lancet 1997;349:847–848

    PubMedWeb of Science
55. Bahn MM, Parchi P. Abnormal diffusion-weighted magnetic resonance images in Creutzfedlt-Jakob disease. Arch Neurol 1999;56:577–583

    CrossRefPubMedWeb of Science
56. Mittal S, Farmer P, Kalina P, Kingsley PB, Halperin J. Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 2002;59:128–134

    CrossRefPubMedWeb of Science
57. Murata T, Shiga Y, Higano S, Takahashi S, Mugikura S. Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. AJNR Am J Neuroradiol 2002;23:1164–1172

    Abstract/FREE Full Text
58. ↵
    Dearmond MA, Kretzschmar HA, Prusiner SB. Prion diseases. In: Graham DI, Lantos PL, eds. Greenfield’s Neuropathology. 7th ed.2002 :273–323
59. ↵
    Matoba M, Tonami H, Miyaji H, Yokota H, Yamamoto I. Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. J Comput Assist Tomogr. 2001;25:274–277

    CrossRefPubMed